Publications by authors named "I Yanguas"
Article Synopsis
- The study examines the use of guselkumab for treating psoriasis in patients with a history of cancer, addressing the limited guidance available for such cases.
- A total of 20 patients were followed over 52 weeks, with high effectiveness rates seen (87.5% achieving a low psoriasis severity score) and a 100% survival rate, including those with active cancers.
- The findings suggest guselkumab is both effective and safe in this population, though the study is limited by its small sample size and retrospective design.*
Background: Although the Spanish Ministry of Health prepares national therapeutic positioning reports (TPRs) and drug reimbursement policies, each of the country's 17 autonomous communities (ACs) is responsible for health care services and prescription requirements in its territory. The aim of the EQUIDAD study was to describe and explore potential differences in prescription requirements for new dermatology drugs across the autonomous communities.
Material And Methods: Cross-sectional study conducted in April and May, 2023.
Background: Although the Spanish Ministry of Health prepares national therapeutic positioning reports (TPRs) and drug reimbursement policies, each of the country's 17 autonomous communities (ACs) is responsible for health care services and prescription requirements in its territory. The aim of the EQUIDAD study was to describe and explore potential differences in prescription requirements for new dermatology drugs across the autonomous communities.
Material And Methods: Cross-sectional study conducted in April and May, 2023.
Article Synopsis
- The Spanish Registry of Primary Cutaneous Lymphomas (RELCP) has analyzed data from 2020 patients over five years, revealing demographic details and treatment outcomes.
- Nearly 75% of patients were diagnosed at stage I, with mycosis fungoides/Sézary syndrome as the most common type (55%).
- The majority of treatments included topical corticosteroids and phototherapy, with a significant percentage achieving complete remission or stability post-treatment.